论文部分内容阅读
目的:对慢性萎缩性胃炎病人进行消化内科规范性治疗的效果进行研究。方法:病例为2013年2月—2015年6月我院慢性萎缩性胃炎病人88例,将其按入院先后顺序随机分为雷贝拉唑组44例与奥美拉唑组44例,均应用消化内科三联规范化治疗。奥美拉唑组病人采用奥美拉唑三联治疗;雷贝拉唑组病人采用雷贝拉唑三联治疗,将两组病人治疗1个月后的疗效进行对比。结果:雷贝拉唑组病人临床总有效率为97.73%(43/44)高于奥美拉唑组病人临床总有效率86.36%(38/44),P<0.05。雷贝拉唑组病人治疗1个月后幽门螺杆菌清除率95.45%(42/44)高于奥美拉唑组病人幽门螺杆菌清除率79.55%(35/44),P<0.05。雷贝拉唑组病人药物副作用发生率4.55%(2/44)低于奥美拉唑组病人药物副作用发生率22.73%(10/44),P<0.05。结论:将雷贝拉唑三联治疗方案应用于慢性萎缩性胃炎病人治疗中,疗效显著,可提高幽门螺杆菌清除率,用药安全性高,值得推广。
Objective: To study the effect of normative treatment of patients with chronic atrophic gastritis. Methods: From February 2013 to June 2015, 88 patients with chronic atrophic gastritis in our hospital were randomly divided into two groups: 44 in the rabeprazole group and 44 in the omeprazole group, Gastroenterology triple standardization of treatment. Omeprazole group patients with omeprazole triple therapy; rabeprazole group with rabeprazole triple therapy, the two groups of patients after 1 month of treatment were compared. Results: The total effective rate of the rabeprazole group was 97.73% (43/44), which was higher than that of the omeprazole group (86.36%, 38/44), P <0.05. The helicobacter pylori clearance rate was 95.45% (42/44) in the rabeprazole group one month later than that in the omeprazole group (79.55%, P <0.05). The side effect rate of drug in rabeprazole group was 4.55% (2/44), which was lower than that in omeprazole group (22.73%, 10/44), P <0.05. Conclusion: The rabeprazole triple therapy in the treatment of chronic atrophic gastritis patients with significant effect, can improve the clearance rate of Helicobacter pylori, drug safety is high, it is worth promoting.